Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Eli Lilly paid $2.8B upfront — a 73.7% upfront-to-TDV ratio — to acquire Atai Life Sciences / Beckley Psytech's psychedelics portfolio. This is the largest psychedelic medicine deal in history and a definitive signal that Big Pharma views next-generation neuropsychiatric small molecules as pipeline-critical assets.
Merck paid $400M upfront for a preclinical KRAS G12D molecular glue — the largest upfront for a preclinical small molecule oncology asset announced in 2026. The SciBrunch Therapeutics Merck deal structure signals a new pricing floor for differentiated KRAS programs and reveals how aggressively big pharma is moving to lock up next-generation RAS inhibitors.
Eli Lilly committed $100M upfront and up to $3.4B in total deal value for access to InnoCare's drug-discovery platform across five undisclosed targets. The InnoCare Eli Lilly deal structure is heavily back-loaded — and that tells you everything about how Big Pharma is pricing platform risk in 2026.
Novartis committed up to $900M to license Boomray's preclinical radioligand therapy platform — a massive bet on an asset with zero clinical data. Here's what the Boomray Novartis deal structure tells us about where radiopharm valuations are headed and what it means for founders sitting on similar programs.
Novo Nordisk paid $300M upfront for a preclinical GLP-1/GIP dual agonist from Hengrui Pharma, with total deal value reaching $2.6B. The Hengrui Pharma Novo Nordisk deal structure reveals how aggressively the obesity market leader is defending its pipeline moat — and resets valuation benchmarks for early-stage metabolic peptides.
GSK paid $110M upfront for a Phase 1 ADC that targets both EGFR and KRAS — two of the most contested targets in oncology — at a total deal value of $1.3B. Here's what the HUTCHMED GSK deal structure tells us about ADC valuations, GSK's pipeline strategy, and what Phase 1 oncology assets should be benchmarking against.
Roche/Genentech committed $190M upfront and up to $2.3B in total deal value for Hanmi Pharmaceutical's Phase 1 metabolic peptide HM17321. The deal structure signals aggressive conviction from Roche in the next wave of metabolic therapeutics — and resets the floor for comparable Phase 1 peptide assets.
Roche paid $190M upfront for a Phase 1 metabolic small molecule — an 8.3% upfront-to-TDV ratio that signals enormous milestone-weighted risk sharing. Here's what the Hanmi Pharmaceutical Roche deal structure tells us about metabolic asset valuations in 2026.
Eli Lilly committed up to $2.9B in total deal value for Merida Biosciences' undisclosed preclinical immunology asset — a striking valuation for a program that hasn't entered the clinic. Here's what the Merida Biosciences Eli Lilly deal structure tells us about where immunology deal-making is headed.
Johnson & Johnson committed $785M upfront — 22.4% of the $3.5B total deal value — for an option on Sail Biomedicines' undisclosed preclinical CAR-T immunology asset. The upfront-to-TDV ratio signals unusually high buyer conviction for a preclinical-stage program. Here's what the Sail Biomedicines, Inc. Johnson & Johnson deal structure means for CAR-T valuations.
Genentech committed $190M upfront to license Hanmi Pharmaceutical's Phase 1 peptide HM17321 in a deal valued at $2.3B. The Hanmi Pharmaceutical Genentech deal structure carries an 8.3% upfront-to-TDV ratio — aggressive risk-sharing that reveals as much about the metabolic space's competitive pressure as it does about buyer conviction.
Johnson & Johnson paid up to $1.0B to acquire Firefly Bio and its preclinical ADC oncology asset — a significant bet on next-generation conjugate technology. Here's what the deal structure tells us about ADC valuations and J&J's strategic calculus.
Roche paid $190M upfront — an 8.3% upfront-to-TDV ratio — for Hanmi Pharm's Phase 1 urocortin 2 analog HM17321, signaling serious conviction in muscle-sparing metabolic mechanisms. Here's what the Hanmi Pharm Roche deal structure tells us about where Big Pharma is placing its next big bets beyond GLP-1.
AstraZeneca's $4.7B option deal with CSPC for next-generation cardiometabolic small molecules is the largest China-originated cardio-licensing transaction announced this year. Here's what the CSPC AstraZeneca deal structure tells us about conviction, risk allocation, and where the cardiometabolic market is heading.
Eli Lilly just dropped $2.3B to acquire LimmaTech Biologics and its vaccine platform — its largest pure-play vaccine bet to date. Here's what the deal structure tells us about Lilly's strategic pivot and what it means for vaccine asset valuations across the board.
Pfizer committed $1.3B upfront — the largest publicly disclosed option payment for a bispecific immuno-oncology asset this year — to lock in 3SBio's bispecific portfolio. The $6.3B total deal value signals Pfizer's aggressive bet that bispecifics will define next-generation I-O, and it resets the valuation floor for every comparable asset in development.
RayzeBio/BMS paid $350M upfront to Philochem for a Phase 1 radiopharmaceutical program in a deal valued at $1.4B. The 25% upfront-to-TDV ratio signals aggressive conviction in targeted radiopharmaceuticals — and resets valuation benchmarks for every Phase 1 radiopharm asset on the market.
AstraZeneca paid $600M upfront — a 40% upfront-to-TDV ratio — to license Dizal Pharmaceutical's approved EGFR inhibitor Zegfrovy in a deal totaling $1.5B. Here's what the Dizal Pharmaceutical AstraZeneca deal structure tells us about where approved oncology small molecules are being priced right now.
Novo Nordisk is paying $2.4B to acquire Omeros and its lead asset zaltenibart. The deal signals aggressive portfolio expansion beyond metabolic disease. Here's what the structure tells us about buyer conviction, strategic logic, and valuation benchmarks for comparable assets.
Pfizer committed $1.2B upfront to license 3SBio / Shenyang Sunshine's PD-1/VEGF bispecific SSGJ-707, with a total deal value of $6.2B. The 19.4% upfront-to-TDV ratio signals high conviction paired with disciplined risk allocation. Here's what the deal structure tells us about bispecific valuations and Pfizer's oncology reboot.
Jazz Pharmaceuticals committed up to $4.0B in total deal value for AbCellera's T cell engager program — one of the largest bispecific collaboration deals of 2026. Here's what the AbCellera Biologics Jazz Pharmaceuticals deal structure tells us about buyer conviction, risk allocation, and where TCE valuations are headed.
AstraZeneca's $18.5B collaboration with CSPC Pharmaceutical for an obesity/chronic disease program marks one of the largest licensing deals of 2026. The $1.2B upfront signals massive buyer conviction, but the deal structure reveals a calculated risk-sharing framework worth dissecting.
Roche committed $700M in total deal value to Nurix Therapeutics for a protein degrader collaboration announced July 9, 2026. The deal structure signals Roche's aggressive re-entry into targeted protein degradation — and resets valuation expectations for the entire modality.
Royalty Pharma committed $2.0B in total deal value to secure a royalty interest in Revolution Medicines' daraxonrasib — a Phase 3 small molecule. Here's what the Revolution Medicines Royalty Pharma deal structure tells us about current mega-deal pricing and what it means for comparable assets in your pipeline.
Eli Lilly is paying $2.3B to acquire Ajax Therapeutics and its small molecule oncology platform — a bold move for an asset with no disclosed phase. Here's what the deal structure tells us about Lilly's conviction and what it means for comparable oncology assets.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.
Try Solidus
